Abstracts tagged "Clinical practice"

Abstract Number: 3211 • 2016 ACR/ARHP Annual Meeting
Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Letty G.A. Versteeg¹, Laura M.M. Steunebrink¹, Ina H. Kuper¹, Harald E. Vonkeman², Peter M. ten Klooster³, Arie E. van der Bijl⁴ and Mart A.F.J. van de Laar⁵, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands, ⁵Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente and University Twente, Enschede, Netherlands
Background/Purpose: Implementation of treat-to-target (T2T) in Rheumatoid Arthritis (RA) leads to limited radiological damage during follow-up of 3 years. Questions are whether these results are…
Abstract Number: 547 • 2016 ACR/ARHP Annual Meeting
Concordance Between Ultrasound Joint Synovitis and Clinical Joint Assessments By Patients or Physicians in Rheumatoid Arthritis
Ayako Hirata¹, Takehisa Ogura¹, Sayaka Takenaka¹, Hideki Ito², Yuki Fujisawa¹, Kennosuke Mizushina¹, Munetsugu Imamura¹, Norihide Hayashi² and Hideto Kameda¹, ¹Department of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan, ²Toho University Ohashi Medical Center, Tokyo, Japan
Background/Purpose: Ultrasonography (US) has been prevalently used as a valid and objective modality for joint examination in patients with rheumatoid arthritis (RA). This study aimed…
Abstract Number: 592 • 2016 ACR/ARHP Annual Meeting
Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis
Grant W. Cannon¹, Alan R. Erickson², Chia-Chen Teng³, Tina Huynh³, Sharon Austin⁴, Bradley S. Stolshek⁵, Alex Mutebi⁶, David Collier⁵, Sally W. Wade⁷ and Brian Sauer³, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴VAMC, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Amgen, Thousand Oaks, CA, ⁶Global Health Economics, Amgen, Thousand Oaks, CA, ⁷Wade Outcomes Research and Consulting, Salt Lake City, UT
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective therapy for rheumatoid arthritis (RA) and have been shown to reduce progression of joint structural damage…
Abstract Number: 705 • 2016 ACR/ARHP Annual Meeting
Is a Positive Family History of Spondyloarthritis of Value in Patients with Chronic Back Pain? Results from Two Large Early Back Pain Cohorts
Zineb Ez-Zaitouni¹, Laure Gossec², Inger Jorid Berg³, Robert Landewé⁴, Maikel van Oosterhout⁵, Mariagrazia Lorenzin⁶, Maxime Dougados⁷, Désirée van der Heijde⁸ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Amsterdam Medical Center, Amsterdam, Netherlands, ⁵Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁶Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, ⁷Paris-Descartes University, Paris, France, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: To assess whether presence of spondyloarthritis (SpA) manifestations in first- and second-degree relatives of patients with chronic back pain (CBP) is associated with higher…
Abstract Number: 729 • 2016 ACR/ARHP Annual Meeting
Does the Presence of Multiple Spondyloarthritis-Features in Patients with Chronic Back Pain Always Lead to Diagnosis of Axial Spondyloarthritis?
Zineb Ez-Zaitouni¹, Pauline Bakker¹, Miranda van Lunteren¹, Inger Jorid Berg², Robert Landewé³, Maikel van Oosterhout⁴, Mariagrazia Lorenzin⁵, Désirée van der Heijde¹ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy
Background/Purpose: The number of clinical spondyloarthritis (SpA)-features plays an important role in the Assessment of SpondyloArthritis international Society (ASAS) modified Berlin algorithm for the diagnostic…
Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Luis Rodriguez Rodriguez¹, Leticia Leon², Inmaculada Morado¹, Zulema Rosales Rosado², Cristina Vadillo Font¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, Benjamín Fernández-Gutiérrez³, Juan A Jover Jover² and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…
Abstract Number: 1409 • 2016 ACR/ARHP Annual Meeting
Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007
Marieke J. de Jonge¹, Laura W.M. Boerboom¹, Anita M.P. Huis¹, Julia M. Weijers¹, Mart A.F.J. van de Laar², Marlies E.J.L. Hulscher¹ and Piet L.C.M. van Riel^1,3, ¹Radboud university medical center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands, ²University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ³Bernhoven, Department of Rheumatology, Uden, Netherlands
Background/Purpose: International guidelines and studies recommend rheumatologists to use validated measures to monitor disease activity, such as the Disease Activity Score of 28 joints (DAS28).…
Abstract Number: 1641 • 2016 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Leticia León¹, Dalifer Freites Núñez², Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Luis Rodriguez Rodriguez¹, Juan A Jover Jover² and Lydia Abásolo Alcázar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than twenty years using Disease Modifying Drugs (DMARDs) is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) but it…
Abstract Number: 1775 • 2016 ACR/ARHP Annual Meeting
Smoking As a Predictor of Cutaneous Activity in Systemic Lupus Erythematosus
Shawn Kwatra¹, Michelle Petri² and Wei Fu³, ¹Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
ACR Abstract Authors: Shawn G. Kwatra1, Wei Fu2, Michelle Petri2 1Department of Dermatology, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD Title:…
Abstract Number: 1802 • 2016 ACR/ARHP Annual Meeting
Prevalence of CMV in the Ohio State University Lupus Population
Brian LaMoreaux¹, Alexa Meara², Holly Steigelman³, Juliette Yedimenko⁴, Wael N. Jarjour⁵ and Stacy P. Ardoin⁶, ¹Rheumatology, Fellow, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴S2056, The Ohio State University, Columbus, OH, ⁵Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Systemic Lupus Erythematous (SLE) is a clinically variable autoimmune disease occurring predominantly in women of childbearing age. SLE treatment can range from close clinical…
Abstract Number: 2213 • 2016 ACR/ARHP Annual Meeting
The Four Stages of Fibromyalgia: Potential for More Precise Treatment Approaches
Mark Gostine¹, Fred Davis¹, Bradley Roberts², Rebecca Risko², Joseph C Cappelleri³, Andrew Clair⁴ and Alesia Sadosky⁵, ¹Michigan Pain Consultants, PC, Grand Rapids, MI, ²ProCare Systems, Inc., Grand Rapids, MI, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer, New York, NY, ⁵Pfizer Inc,, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and tenderness making it difficult to manage. Accounting for FM heterogeneity might elicit an improvement in…
Abstract Number: 2318 • 2016 ACR/ARHP Annual Meeting
Real World Use of the Myositis Autoantibody Panel
Jason Weiner¹, Ryan Jessee², Robert T. Keenan³, Michael Datto⁴ and Lisa Criscione-Schreiber⁵, ¹Division of Rheumatology, Duke University, Durham, NC, ²Division of Internal Medicine, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC, ⁴Division of Pathology, Duke University, Durham, NC, ⁵Division of Rheumatology, Department of Medicine, Duke University, Durham, NC
Background/Purpose: The identification of myositis specific and associated autoantibodies occurring in idiopathic inflammatory myopathies (IIMs) has improved classification and prognosis determinations. With commercial availability, these…
Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 2686 • 2016 ACR/ARHP Annual Meeting
Objective Improvement in Fatigue Scores for Primary Sjögren’s Patients Receiving a Tailored Multidisciplinary Fatigue Intervention in a Generic Fatigue Clinic
Katie Hackett^1,2, Robert Forder³, Dennis W Lendrem⁴, Ben Hargreaves⁵, Victoria Strassheim^1,3, Zoe Gotts³, Vincent Deary^1,6, Wan-Fai Ng^7,8 and Julia Newton^1,3, ¹CRESTA Fatigue Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶School of Health Psychology, Northumbia University, Newcastle upon Tyne, United Kingdom, ⁷Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, ⁸Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (PSS) is an autoimmune disease which targets secretary glands resulting in dry eyes and mouth. Approximately 70% of PSS patients experience…
Abstract Number: 506 • 2015 ACR/ARHP Annual Meeting
Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
Alan K. Matsumoto¹, Herbert S. B. Baraf², Janna Radtchenko³, Jason Drenning⁴ and Bruce Feinberg⁵, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²The Center for Rheumatology and Bone Research, Wheaton, MD, ³Health Care Analytics, Cardinal Health, Dallas, TX, ⁴Healthcare Analytics, Cardinal health, Dallas, TX, ⁵Cardinal Health, Dublin, OH
Background/Purpose: Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].